LSL Pharma Group Inc.
LSL.V
TSX
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 16.45% | 68.33% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 16.45% | 68.33% | |||
| Cost of Revenue | 9.37% | 65.14% | |||
| Gross Profit | 122.57% | 137.24% | |||
| SG&A Expenses | -6.32% | 2.99% | |||
| Depreciation & Amortization | 411.75% | 120.69% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.97% | 56.65% | |||
| Operating Income | 41.20% | -6.89% | |||
| Income Before Tax | 22.07% | -143.24% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 22.07% | -157.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 22.07% | -157.66% | |||
| EBIT | 41.20% | -6.89% | |||
| EBITDA | 97.41% | 34.84% | |||
| EPS Basic | 21.88% | -146.15% | |||
| Normalized Basic EPS | 22.00% | -7.53% | |||
| EPS Diluted | 11.88% | -146.15% | |||
| Normalized Diluted EPS | 22.00% | -7.53% | |||
| Average Basic Shares Outstanding | 0.00% | 4.04% | |||
| Average Diluted Shares Outstanding | -0.05% | 4.10% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||